DOI QR코드

DOI QR Code

Ability of Biochemical Parameters to Distinguish between Bile Duct Cancer and Gall Bladder Stones - A Case Control Study in a Tertiary Care Hospital of Pokhara Valley

  • Published : 2013.02.28

Abstract

Background: The present study was designed to comparatively assess alteration of biochemical parameters in bile duct cancer and gall stone disease. Materials and Methods: A hospital based case-control study was carried out in the Department of Biochemistry of Manipal Teaching Hospital, Pokhara, Nepal between $1^{st}$ January 2010 and $31^{st}$ December 2012. The variables collected were age, gender, serum total cholesterol, total bilirubin, AST, ALT, serum alkaline phosphatase, albumin and hemoglobin. One way ANOVA was used to examine the statistical significance of differences between groups. A post-hoc LSD test was applied for the comparison of means of control versus case groups. A p-value of <0.05 (two-tailed) was considered significant. Results: The mean age of cases and controls was $53.2{\pm}21.2$ years. The levels of serum cholesterol were higher in cases of cancer $192.5{\pm}21.5$ mg/dl in comparison to stone cases $168.7{\pm}16.1$ mg/dl (p value: 0.0001). The total bilirubin showed the marked difference in cases of cancer $7.6{\pm}3.2$ mg/dl in comparison to stone cases $2.5{\pm}0.8$ mg/dl of bile duct. There was discernible divergence in values of alkaline phosphatase in cases of cancer $251.5{\pm}20.1$ IU/l when compared to stone cases $173.2{\pm}12.6$ IU/l of bile duct. In contrast, there was no apparent deviation in values of aspartate transaminases and alanine transaminases in cases of cancer $59.1{\pm}8.9$ IU/l and $105.5{\pm}26.5$ IU/l when compared to stone cases $56.9{\pm}7.9$ IU/l and $84.5{\pm}13.5$ IU/l respectively. Conclusions: LFT analysis for pre-operative assessment was a good predictive marker in setting apart bile duct cancer and gall bladder stone.

Keywords

References

  1. Andreotti G, Chen J, Gao YT, et al (2008). Serum lipid levels and the risk of biliary tract cancers and biliary stones: a population-based study in China. Int J Cancer, 122, 2322-9.
  2. Bhudhisawasdi V, Muisuk K, Areejitranusorn P, et al (2004). Clinical value of biliary alkaline phosphatase in non-jaundiced cholangiocarcinoma. J Cancer Res Clin Oncol, 130, 87-92. https://doi.org/10.1007/s00432-003-0515-x
  3. Biddinger SB, Haas JT, Yu BB, et al (2008). Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med, 14, 778-82. https://doi.org/10.1038/nm1785
  4. Doumas BT, Watson WA, Biggs HG (1971). Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta, 31, 87-96. https://doi.org/10.1016/0009-8981(71)90365-2
  5. Garber CC (1981). Jendrassik--Grof analysis for total and direct bilirubin in serum with a centrifugal analyzer. Clin Chem, 27, 1410-6.
  6. German Society for Clinical Chemistry (1972). Standard method fordetermination of alkaline phosphatase (AP) activity. J Clin Chem Clin Biochem, 10, 290.
  7. Gong AK, Backenstose B (1999). Evaluation of the HB-Quick: a portable hemoglobinometer. J Clin Monit Comput, 15, 171-7. https://doi.org/10.1023/A:1009946603422
  8. Habib L, Mirza MR, Channa MA, et al (2009). Role of liver function tests in symptomatic Cholelithiasis. J Ayub Med Coll Abbottabad, 21, 117-9.
  9. Henley KS, Pollard HM (1955). A new method for the determination of glutamic oxalacetic and glutamic pyruvic transaminase in plasma. J Lab Clin Med, 46, 785.
  10. Jeong PY, Byung PK, Jun KS, et al (2006). Bile acid analysis in biliary tract cancer. Yonsei Med J, 47, 817-25. https://doi.org/10.3349/ymj.2006.47.6.817
  11. Kumar S, Masood N, Shaikh AJ, et al (2009). Clinical presentation and outcomes of patients with biliary malignancies: the Aga Khan University experience. Asian Pac J Cancer Prev, 10, 463-6.
  12. Luke C, Price T, Roder D (2010). Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population. Asian Pac J Cancer Prev, 11, 1479-85.
  13. Nishino H (2006). High risk factors for bile duct cancer. Nihon Rinsho, 64, 439-42.
  14. Park JY, Park BK, Ko JS, et al (2006). Bile acid analysis in biliary tract cancer. Yonsei Med J, 47, 817-25. https://doi.org/10.3349/ymj.2006.47.6.817
  15. Premkumar M, Sable T (2012). Obesity, dyslipidemia and cholesterol gallstone disease during one year of Antarctic residence. Rural Remote Health, 12, 2186.
  16. Schirmer BD, Winters KL, Edlich RF, (2005). Cholelithiasis and cholecystitis. J Long Term Eff Med Implants, 15, 329-38. https://doi.org/10.1615/JLongTermEffMedImplants.v15.i3.90
  17. Trinder P (1969). Determination of serum cholesterol by enzymatic colorimetric method. Ann Clin Biochem, 6, 24-7. https://doi.org/10.1177/000456326900600108
  18. Xu HL, Cheng JR, Andreotti G, et al (2011). Cholesterol metabolism gene polymorphisms and the risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Carcinogenesis, 32, 58-62. https://doi.org/10.1093/carcin/bgq194
  19. Zare M, Kargar S, Akhondi M, et al (2011). Role of liver function enzymes in diagnosis of choledocholithiasis in biliary colic patients. Acta Med Iran, 49, 663-6.

Cited by

  1. Association of Cytochrome-17 (MspA1) Gene Polymorphism with Risk of Gall Bladder Stones and Cancer in North India vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5557